CALIXAR appears in many different kinds of news where we display our expertise and technology throughout the world.
Home / Media / Press Releases
Calixar invests €1 million in pipeline of highly druggable membrane protein targets and native antigens.
CALIXAR enters into collaboration with Kobe University to explore stabilized native membrane protein dynamics in reconstituted membranes using fluorescence.
Calixar launches new funding round to establish business strategy.
CALIXAR enters into Cryo-EM collaboration with CBI/IGBMC to unlock structure-based drug design for challenging membrane protein targets.
CALIXAR and COSMO BIO to conclude distribution agreement.
Biotem enters into collaboration with Calixar for the development of therapeutic antibodies against membrane protein targets.
Calixar signs exclusive licensing agreement with Regeneron on undisclosed therapeutic target.
Calixar announces a collaborative research agreement with Thermo Fisher Scientific on multiple membrane proteins of high relevance to drug discovery.
CALIXAR and ASTRAZENECA to publish new insight on KCC2 architecture and function in Scientific Reports.
CALIXAR and University of Avignon to launch new research lab developing innovative chemistry for target discovery.
CALIXAR and Biouniversa to publish unprecedented new insights on Pancreatic Ductal Adenocarcinoma (PDAC) in Nature Communications.
CALIXAR raises €1 Million.
CALIXAR and ASTON University collaboration on multidrug resistance targets.
Major Breakthrough in Influenza Vaccines.
New strategic compounds: CALIXAR to extend its portfolio of strategic compounds for complex pharmaceutical target isolation.
ABL Strategic Marketing.
CALIXAR closes an initial €875,000 funding round.
Starting from native material or recombinant systems, we succeed with all types of membrane proteins: GPCRs, Ions Channels, Transporters, Receptors and Viral Proteins.
© 2020 Calixar. All rights reserved.